Research

Mixed

Roux-en-Y gastric bypass (RYGB) provides superior long-term type 2 diabetes (T2DM) remission, lower relapse rates, and better glycemic control compared to sleeve gastrectomy (SG) in real-world clinical settings.

If you have Type 2 Diabetes and are considering bariatric surgery, Roux-en-Y Gastric Bypass (RYGB) is associated with better long-term diabetes remission and lower relapse rates compared to Sleeve Gastrectomy (SG). While SG is a common procedure, RYGB may offer superior metabolic benefits for diabetes management, though it involves a more complex surgery. Discuss these long-term outcomes with your surgeon to make an informed choice.

GoodSupportsHIGH confidence
In this large multicenter study, patients who had RYGB had greater weight loss, a slightly higher T2DM remission rate, less T2DM relapse, and better long-term glycemic control compared with those who had SG.
Kathleen M. McTigue et al. · JAMA Surgery · 2020

Why this rating

Large multicenter cohort study (n=9710) with long-term follow-up (up to 5 years) and rigorous statistical adjustment, though observational design limits causal inference compared to RCTs.

Source

Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass

Kathleen M. McTigue et al. · JAMA Surgery · 2020

DOI 10.1001/jamasurg.2020.0087

cohort · n=9710Cited 219×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →